New defense tested for transplant patients at highest risk of dangerous virus
NCT ID NCT06958796
Summary
This study is testing whether giving antibody infusions (CytoGam®) after standard preventive antiviral medication ends can help prevent late CMV infection in high-risk organ transplant patients. It will enroll 80 adults who received a kidney, liver, or combined liver-kidney transplant and are at the highest risk for CMV because their donor had the virus but they never did. The goal is to see if these antibody infusions provide extra protection during the vulnerable period after standard prevention stops.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER TRANSPLANT; COMPLICATIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Texas Southwestern
RECRUITINGDallas, Texas, 75390, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.